Privium Fund Management B.V. Has $539,000 Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Privium Fund Management B.V. raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 7.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,016 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Privium Fund Management B.V.’s holdings in Dyne Therapeutics were worth $539,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Concurrent Investment Advisors LLC bought a new position in shares of Dyne Therapeutics in the first quarter valued at approximately $573,000. Sei Investments Co. bought a new position in Dyne Therapeutics during the 1st quarter valued at $693,000. Oppenheimer & Co. Inc. purchased a new position in Dyne Therapeutics during the 1st quarter worth $810,000. Seven Eight Capital LP bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth $516,000. Finally, Swiss National Bank raised its holdings in shares of Dyne Therapeutics by 41.5% in the first quarter. Swiss National Bank now owns 85,200 shares of the company’s stock valued at $2,419,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on DYN. Morgan Stanley boosted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus upped their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Oppenheimer reiterated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.60.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $28.48 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.04 and a fifty-two week high of $47.45. The business has a 50-day moving average of $33.05 and a 200 day moving average of $34.99. The firm has a market cap of $2.86 billion, a P/E ratio of -7.93 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the sale, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Oxana Beskrovnaya sold 2,339 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the sale, the insider now directly owns 140,375 shares in the company, valued at approximately $4,849,956.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.